tetano
Editor, Senior Moderator
J Immunol Res. 2016;2016:4131324. doi: 10.1155/2016/4131324. Epub 2016 Dec 19.
[h=1]Yeast Surface-Displayed H5N1 Avian Influenza Vaccines.[/h] Lei H[SUP]1[/SUP], Jin S[SUP]1[/SUP], Karlsson E[SUP]2[/SUP], Schultz-Cherry S[SUP]2[/SUP], Ye K[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Highly pathogenic H5N1 avian influenza viruses pose a pandemic threat to human health. A rapid vaccine production against fast outbreak is desired. We report, herein, a paradigm-shift influenza vaccine technology by presenting H5N1 hemagglutinin (HA) to the surface of yeast. We demonstrated, for the first time, that the HA surface-presented yeast can be used as influenza vaccines to elicit both humoral and cell-mediated immunity in mice. The HI titer of antisera reached up to 128 in vaccinated mice. A high level of H5N1 HA-specific IgG1 and IgG2a antibody production was detected after boost immunization. Furthermore, we demonstrated that the yeast surface-displayed HA preserves its antigenic sites. It preferentially binds to both avian- and human-type receptors. In addition, the vaccine exhibited high cross-reactivity to both homologous and heterologous H5N1 viruses. A high level production of anti-HA antibodies was detected in the mice five months after vaccination. Finally, our animal experimental results indicated that the yeast vaccine offered complete protection of mice from lethal H5N1 virus challenge. No severe side effect of yeast vaccines was noted in animal studies. This new technology allows for rapid and large-scale production of influenza vaccines for prepandemic preparation.
PMID: 28078309 DOI: 10.1155/2016/4131324
[PubMed - in process] Free full text
[h=1]Yeast Surface-Displayed H5N1 Avian Influenza Vaccines.[/h] Lei H[SUP]1[/SUP], Jin S[SUP]1[/SUP], Karlsson E[SUP]2[/SUP], Schultz-Cherry S[SUP]2[/SUP], Ye K[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Highly pathogenic H5N1 avian influenza viruses pose a pandemic threat to human health. A rapid vaccine production against fast outbreak is desired. We report, herein, a paradigm-shift influenza vaccine technology by presenting H5N1 hemagglutinin (HA) to the surface of yeast. We demonstrated, for the first time, that the HA surface-presented yeast can be used as influenza vaccines to elicit both humoral and cell-mediated immunity in mice. The HI titer of antisera reached up to 128 in vaccinated mice. A high level of H5N1 HA-specific IgG1 and IgG2a antibody production was detected after boost immunization. Furthermore, we demonstrated that the yeast surface-displayed HA preserves its antigenic sites. It preferentially binds to both avian- and human-type receptors. In addition, the vaccine exhibited high cross-reactivity to both homologous and heterologous H5N1 viruses. A high level production of anti-HA antibodies was detected in the mice five months after vaccination. Finally, our animal experimental results indicated that the yeast vaccine offered complete protection of mice from lethal H5N1 virus challenge. No severe side effect of yeast vaccines was noted in animal studies. This new technology allows for rapid and large-scale production of influenza vaccines for prepandemic preparation.
PMID: 28078309 DOI: 10.1155/2016/4131324
[PubMed - in process] Free full text
